Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Vanderbilt University
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosed with melanoma with a BRAF mutation and relapse following therapy with a BRAF inhibitor
Enrolled in a clinical trial through the Vanderbilt Ingram Cancer Center (VICC) including an arm with an oral Akt inhibitor
Able and willing to provide informed consent
You may not be if
Factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies or an unpredictable schedule
Unable to give informed consent
Clareo Health | Autonomic Phenotype Before and After Akt Inhibition
